Investor Presentaiton
Financial Forecasts for FY2023
Revenue of Major Products in Japan
FY2022
FY2023
Results
Forecasts
Value
%
Change
Billions of yen
Revenue will decrease ¥21.1B on
Japan segment total
EquaⓇ/EquMetⓇ
33.6
32.4
(1.2)
(3.4)
TRERIEF
16.7
15.0
(1.7)
(10.0)
LATUDAⓇ
9.6
12.5
2.9
30.5
Sales of LATUDAⓇ and
METGLUCO®
7.7
7.5
(0.2)
(2.6)
TWYMEEGⓇ are expected to
increase
TWYMEEG
2.2
4.2
2.0
89.3
LONASEN Tape
2.9
3.3
0.4
12.2
AG products
9.2
8.6
(0.6)
(6.1)
TrulicityⓇ*
24.8
-
(24.8)
Others
19.5
21.5
2.0
Total
126.1
105.0
(21.1)
10.3
(16.7)
Note: Sales of each product are shown by invoice price (* Trulicity is shown by NHI price)
Sales collaboration of TrulicityⓇ
was terminated in December 2022
NHI price revision impact in
FY2023 (approx.\5.0B)
Sumitomo Pharma
© Sumitomo Pharma Co., Ltd. All Rights Reserved. 13View entire presentation